Market Closed -
Other stock markets
|
After market 12:25:57 | |||
150 EUR | -1.19% | 150 | +0.02% |
07:21am | Habeck's 'pharma trip' - industry sees structural problems | DP |
04-26 | Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board | DP |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- With an enterprise value anticipated at 3.42 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.06% | 70.44B | A | ||
+10.97% | 8.94B | A- | ||
-14.44% | 4.75B | A- | ||
+43.48% | 4.5B | - | ||
+5.96% | 3.85B | B- | ||
+23.46% | 2.38B | B | ||
-21.36% | 2.34B | C- | ||
-27.04% | 2.2B | - | ||
+7.97% | 1.96B | - | - | |
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA